United States - English - NLM (National Library of Medicine)

forest pharmaceuticals, inc. - flunisolide hemihydrate (unii: qk4dys664x) (flunisolide - unii:qk4dys664x) - aerosol, metered - 80 ug - aerospan inhalation aerosol is indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients 6 years of age and older. aerospan inhalation aerosol is also indicated for asthma patients requiring oral corticosteroid therapy, where adding aerospan inhalation aerosol may reduce or eliminate the need for oral corticosteroids. aerospan inhalation aerosol is not indicated for the relief of acute bronchospasm. aerospan inhalation aerosol is contraindicated in the primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required. hypersensitivity to flunisolide or any of the ingredients of this preparation contraindicates the use of aerospan inhalation aerosol.

United States - English - NLM (National Library of Medicine)

forest pharmaceuticals, inc. - rimantadine hydrochloride (unii: jei07oos8y) (rimantadine - unii:0t2ef4jqtu) - tablet - 100 mg - flumadine is indicated for the prophylaxis and treatment of illness caused by various strains of influenza a virus in adults. flumadine is indicated for prophylaxis against influenza a virus in children. prophylaxis: in controlled studies of children over the age of 1 year, healthy adults and elderly patients, flumadine has been shown to be safe and effective in preventing signs and symptoms of infection caused by various strains of influenza a virus. early vaccination on an annual basis as recommended by the centers for disease control's immunization practices advisory committee is the method of choice in the prophylaxis of influenza unless vaccination is contraindicated, not available or not feasible. since flumadine does not completely prevent the host immune response to influenza a infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically-related viruses. following vaccination during an influenza

United States - English - NLM (National Library of Medicine)

forest pharmaceuticals, inc. - theophylline, anhydrous (unii: 0i55128jyk) (theophylline, anhydrous - unii:0i55128jyk) - liquid - 80 mg in 15 ml - theophylline is indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis. elixophyllin elixir is contraindicated in patients with a history of hypersensitivity to theophylline or other components in the product.

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - ketorolac tromethamine (unii: 4eve5946bq) (ketorolac - unii:yzi5105v0l) - ketorolac tromethamine 60 mg in 2 ml - carefully consider the potential benefits and risks of ketorolac tromethamine and other treatment options before deciding to use ketorolac. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). acute pain in adult patients ketorolac tromethamine is indicated for the short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. therapy should always be initiated with intravenous or intramuscular dosing of ketorolac tromethamine, and oral ketorolac tromethamine is to be used only as continuation treatment, if necessary. the total combined duration of use of ketorolac tromethamine injection and oral ketorolac tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see warnings, precautions, dosage and administration, and   adverse reactions ). patie

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - ketorolac tromethamine (unii: 4eve5946bq) (ketorolac - unii:yzi5105v0l) - carefully consider the potential benefits and risks of ketorolac tromethamine and other treatment options before deciding to use ketorolac. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). acute pain in adult patients ketorolac tromethamine is indicated for the short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. therapy should always be initiated with intravenous or intramuscular dosing of ketorolac tromethamine, and oral ketorolac tromethamine is to be used only as continuation treatment, if necessary. the total combined duration of use of ketorolac tromethamine injection and oral ketorolac tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see warnings, precautions, dosage and administr

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - ketorolac tromethamine (unii: 4eve5946bq) (ketorolac - unii:yzi5105v0l) - carefully consider the potential benefits and risks of ketorolac tromethamine and other treatment options before deciding to use ketorolac. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). acute pain in adult patients ketorolac tromethamine is indicated for the short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. therapy should always be initiated with intravenous or intramuscular dosing of ketorolac tromethamine, and oral ketorolac tromethamine is to be used only as continuation treatment, if necessary. the total combined duration of use of ketorolac tromethamine injection and oral ketorolac tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see warnings, precautions, dosage and administr

United States - English - NLM (National Library of Medicine)

rebel distributors corp - thyroid (unii: 0b4fdl9i6p) (thyroid - unii:0b4fdl9i6p) - thyroid 15 mg - armour thyroid tablets are indicated: - as replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. this category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (see warnings). - as pituitary tsh suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic iymphocytic thyroiditis (hashimoto's), multinodular goiter, and in the management of thyroid cancer. thyroid hormone preparations are generally contraindicated in patients with diagnosed but as yet uncorrected

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - milnacipran hydrochloride (unii: rnz43o5ww5) (milnacipran - unii:g56vk1hf36) - milnacipran hydrochloride 50 mg - savella is indicated for the management of fibromyalgia. savella is not approved for use in pediatric patients [see use in specific populations (8.4)]. concomitant use of savella in patients taking monoamine oxidase inhibitors (maois) is contraindicated. in patients receiving a serotonin reuptake inhibitor in combination with a monoamine oxidase inhibitor (maoi), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma. these reactions have also been reported in patients who have recently discontinued serotonin reuptake inhibitors and have been started on an maoi. some cases presented with features resembling neuroleptic malignant syndrome. the effects of combined use of savella and maois have not been evaluated in humans. therefore, it is recommended that savella should not be used in combination wit

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - pantoprazole sodium (unii: 6871619q5x) (pantoprazole - unii:d8tst4o562) - pantoprazole 20 mg - pantoprazole sodium  delayed-release tablets are indicated for: pantoprazole sodium  delayed-release tablets are indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis (ee). for those adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of pantoprazole sodium  delayed-release tablets may be considered. safety of treatment beyond 8 weeks in pediatric patients has not been established. pantoprazole sodium  delayed-release tablets are indicated for maintenance of healing of ee and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerd. controlled studies did not extend beyond 12 months. pantoprazole sodium  delayed-release tablets are indicated for the long-term treatment of pathological hypersecretory conditions, including zollinger-ellison syndrome. teratogenic effects pregnancy category c  repr

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - gentamicin sulfate (unii: 8x7386qrlv) (gentamicin - unii:t6z9v48ikg) - gentamicin 3 mg in 1 g - gentamicin sulfate ophthalmic ointment is indicated in the topical treatment of ocular bacterial infections including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharonconjunctivitis: acute meibomianitis, and dacryocystitis, caused by susceptible strains of the following microorganisms: gentamicin sulfate ophthalmic ointment is con-traindicated in patients with known hypersensitivity to any of the components.